-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Balapiravir hydrochloride
![{PARAM:[Name]}({[CAS]})](https://resource.bocsci.com/structure/690270-65-6.gif)
| Category | Hepatitis C Virus (HCV) |
| CAS | 690270-65-6 |
| Description | Balapiravir hydrochloride is an orally active prodrug of a nucleoside analogue inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase (RdRp). It is an NS5B inhibitor that has the potential to treat HCV infection. |
Product Information
| Synonyms | Ro 4588161 hydrochloride; R1626 hydrochloride; (2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-2-azido-2-((isobutyryloxy)methyl)tetrahydrofuran-3,4-diyl bis(2-methylpropanoate) hydrochloride; 4'-C-azido-2',3',5'-tris(2-methylpropanoate)cytidine monohydrochloride; 4-Amino-1-(4-C-azido-2',3',5'-tri-O-(2-methylpropanoyl)-β-D-ribofuranosyl)pyrimidin-2(1H)-one monohydrochloride |
| IUPAC Name | [(2R,3S,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-azido-3,4-bis(2-methylpropanoyloxy)oxolan-2-yl]methyl 2-methylpropanoate;hydrochloride |
| Molecular Weight | 530.96 |
| Molecular Formula | C21H31ClN6O8 |
| Canonical SMILES | CC(C)C(=O)OCC1(C(C(C(O1)N2C=CC(=NC2=O)N)OC(=O)C(C)C)OC(=O)C(C)C)N=[N+]=[N-].Cl |
| InChI | InChI=1S/C21H30N6O8.ClH/c1-10(2)17(28)32-9-21(25-26-23)15(34-19(30)12(5)6)14(33-18(29)11(3)4)16(35-21)27-8-7-13(22)24-20(27)31;/h7-8,10-12,14-16H,9H2,1-6H3,(H2,22,24,31);1H/t14-,15+,16-,21-;/m1./s1 |
| InChIKey | RAJFQMDUVDHLII-PYZPAVLJSA-N |
| Purity | ≥98% (HPLC) |
| Solubility | Soluble in DMSO |
| Appearance | Solid Powder |
| Storage | Store at 2-8°C for short term (days to weeks) or -20°C for long term (months to years) |
| Complexity | 971 |
| Exact Mass | 530.1891897 |
| In Vitro | After oral dosing of the CD-1 mice with 28.1 mg/kg of balapiravir (Ro 4588161; R1626), R1479 reaches a Cmax and a minimum concentration in plasma (Cmin) of 24.38 μM and 6.34 μM, respectively, at 2 h and 24 h postdosing, |
| PSA | 199.78000 |
| Target | HCV; DNA/RNA Synthesis |